Fortis Malar Hospitals Ltd.
Snapshot View

65.00 -0.50 ▼-0.8%

30 July 2021, 04:00:00 P.M.
Volume: 6,954

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.fortismalar.com
Financial Indicators
Market Cap 122.76 Cr.
Earnings per share (EPS) -4.20 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 228.60 Trailing Twelve Months Ending 2021-03
Book Value / Share 47.34 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.38 Calculated using Price: 65.50
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.87 Cr. 18,741,759 Shares
FaceValue 10
Company Profile

Malar Hospitals (an Associate of Fortis Healthcare), like every other Fortis hospital, is a manifestation of the founder’s vision of creating a world-class integrated healthcare delivery system in India, entailing the finest medical skills combined with compassionate patient care.

Malar Hospitals is one of India’s leading multi-specialty hospitals. Founded in 1992 and located in Chennai near the famous Theosophical Society, Adyar. Malar Hospitals is equipped with ultra-modern medical infrastructure that is on par with the best in the world. Among the faculty are renowned consultants with decades of experience and excellence in their fields.Dr.S.Ramamurthy , the chief promoter and  Chairman and Managing Director of Malar Hospitals Ltd is Family consulatant and Sonoligist since 1979. He has been an NRI since 1979 to February 1986. He was a Medical Officer and Consultant in charge of Fudo consortium cilinic owned by Japanease Firm Yanbu at Saudi Arabia 

Malar Hospitals is a leading centre for cardiac care, renal transplants, neurosurgery, oto- laryngocoloy, limb reconstruction surgery and maxillo facial orthodontology. It also has one of South India’s best trauma care centers.

Since the beginning, Malar Hospitals has been serving clients from across India, South East Asia and the Middle East - with the singular objective of providing Humane Care for Human Cure.

The Department of Orthopedic Surgery of Malar Hospitals is a reputed centre for trauma care in India. The orthopedic team offers comprehensive, specialized care for all trauma and cold orthopedic conditions. All out-patients are treated in the orthopedic clinic. Intra- articular injections and needling of trigger spots are performed in the injection clinic as out-patient procedures. In-patient and post-operative patients are seen during the twice-a-day ward rounds. All orthopedic and trauma surgeries are performed in a state-of-the-art exclusive orthopedic operation theatre, which is equipped with an image intensifier, orthopedic fracture table, arthroscopy system, Swiss-made operating instruments and all orthopedic implants and prostheses.

The highly experienced team of anesthesiologists of Malar Hospital can handle any emergency situation or high- risk patient. They have highly experienced operating - theatre staff and technicians who ensure smooth and safe conduct of all surgeries.

Malar Hospital, with 180 beds, focuses on providing comprehensive medical care in the areas of cardiology and cardiac surgery, gynecology, orthopedics, gastroenterology, neurology, pediatrics, diabetics, and nephrology.

Malar Hospitals also has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Pediatric Cardiac surgeries, Orthopedics and Joint replacement, Neurosurgery and Plastic reconstruction surgeries have been performed in this hospital.  The hospital’s Obstetrics and Gynecology services are among the busiest in the city, performing many difficult deliveries and surgeries successfully, and are supported by a dedicated Neonatology unit.

Malar Hospital's Escorts Heart Centre had tied up with Aishwarya Trust to help poor children with congenital heart defect (CHD) as part of the government scheme Ilam Sirar Iruthaya Pathukappu Thittam.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.76%
1 Week
+0.62%
1 Month
-0.99%
3 Month
+6.21%
6 Month
+22.64%
1 Year
+36.41%
2 Year
+29.87%
5 Year
+22.76%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 26.08 78.53 10.84 8.93 6.80 3.16 3.28 1.97 -8.82
Return on Capital Employed (%) 32.80 97.46 17.10 14.17 10.96 5.00 5.90 3.17 -4.09
Return on Assets (%) 9.30 41.57 9.13 6.85 4.97 2.40 2.40 1.39 -5.27

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 34 77 85 91 98 100 103 105 96
Non Curr. Liab. 7 1 1 0 0 0 0 0 56
Curr. Liab. 78 13 16 37 32 30 45 44 36
Minority Int.
Equity & Liab. 118 91 101 128 130 130 148 149 188
Non Curr. Assets 44 18 20 20 28 33 34 37 126
Curr. Assets 75 73 82 108 102 97 113 112 62
Misc. Exp. not W/O
Total Assets 118 91 101 128 130 130 148 149 188

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 95 98 108 118 130 141 149 145 112
Other Income 0 5 7 8 9 8 8 10 11
Total Income 95 102 115 126 138 149 158 155 123
Total Expenditure -81 -86 -99 -110 -124 -140 -147 -147 -115
PBIDT 14 16 16 15 14 9 10 8 8
Interest -1 -1 0 -1 0 0 0 -1 -8
Depreciation -3 -2 -2 -3 -3 -4 -4 -4 -13
Taxation -3 -13 -5 -4 -4 -1 -2 -1 3
Exceptional Items 1 44 -1
PAT 8 43 9 8 6 3 3 2 -9

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 11 -64 5 4 10 -9 9 -16 0
Cash Fr. Inv. -10 73 -1 5 -22 13 -2 6 50
Cash Fr. Finan. -1 -7 -1 -1 -1 0 0 -12
Net Change 0 2 3 10 -13 4 7 -9 38
Cash & Cash Eqvt 1 3 6 16 3 7 15 5 43

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 62.71 62.71 62.71 62.71 62.71 62.71 62.71 62.71 62.71
Public 37.29 37.29 37.29 37.29 37.29 37.29 37.29 37.29 37.29
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 47.84 47.84 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find enclosed details of the voting results of the 30th Annual General Meeting of the Company held on Thursday 29th July 2021 at 2.00 P.M. (IST) in the format as prescribed under Regulation 44(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 together with combined scrutinizers report.

This is for your information and records.
Thu, 29 Jul 2021
Shareholder Meeting / Postal Ballot-Outcome of AGM
It is hereby informed that 30th Annual General Meeting (30th AGM) of the Members of Fortis Malar Hospitals Limited (the Company) was held on Thursday July 29 2021 at 2:00 P.M (IST) through Video Conferencing/ Other Audio Visual Means (VC/OAVM) in compliance with various circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India.
Tue, 27 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it is hereby informed that the Company is in the receipt of request for issuance of duplicate share certificate due of loss of certificates.

You are requested to take the same on your record.

Technical Scans View Details

Thu, 29 Jul 2021
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Closing Near 50 EMA Closing Near 50 EMA

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 774.00 +10.1%
Divi's Laboratories Ltd. 128,656.69 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,712.70 +0.9%
Cipla Ltd. 71,170.06 920.30 +4.3%
Cadila Healthcare Ltd. 58,547.84 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,214.94 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 29.59 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 3.88 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%